Diligence memo · auto-generated · as of July 2, 2026
Attralus, Inc.
Attralus, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Attralus, Inc. operates in Biotechnology, based in Burlingame.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Attralus, Inc. has raised $173M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $117M on 2021-08-31.
Most recent recorded round closed around 2024-01-26.
Valuation (modeled)modeled
Provath models Attralus, Inc. at approximately $709M (range $254M–$1.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.35× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 25 months.
Last raise 2.4 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 2.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 96% of Biotechnology peers (4293 compared).
Modeled value ranks above 86% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.